SCHEMBL23833490

SCHEMBL23833490

COc1ncc(NC(=O)c2cn(C)c3ncccc23)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
HTR2C P28335 1/20 0.42
IDH1 O75874 4/20 0.42
MALT1 Q9UDY8 1/20 0.41
GRM4 Q14833 1/20 0.41
ALDH1A1 P00352 3/20 0.40
APOBEC3G Q9HC16 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR3 Q99500 1/20 0.40
AVPR2 P30518 1/20 0.40
GPR27 Q9NS67 1/20 0.40
NPC1 O15118 1/20 0.40
TSHR P16473 1/20 0.40
NAMPT P43490 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MITF O75030 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30150995 1.00 MAPT (0.46) MAPTPOLBGAAHTR2CIDH1
SCHEMBL23840486 0.91 IDH1 (0.40) MAPTPOLBGAAIDH1MEN1
SCHEMBL25758644 0.88 LMNA (0.51) MAPTPOLBGAAIDH1GRM4
SCHEMBL23833429 0.87 HTR2C (0.43) MAPTPOLBGAAHTR2CMALT1
SCHEMBL30151060 0.87 HTR2C (0.43) MAPTPOLBGAAHTR2CMALT1
SCHEMBL23846447 0.79 MAPT (0.46) MAPTPOLBGAAIDH1MEN1
SCHEMBL23840599 0.78 PIK3C3 (0.36) MAPTPOLBGAAHTR2CIDH1
SCHEMBL30151035 0.77 MAPT (0.44) MAPTPOLBGAAIDH1GRM4
SCHEMBL23833408 0.77 MAPT (0.44) MAPTPOLBGAAIDH1GRM4
SCHEMBL23833480 0.77 GPR27 (0.48) MAPTPOLBGAAIDH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MAPT 66/4885POLB 2069/4885GAA 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.